Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

March 3, 2021

Study Completion Date

October 27, 2021

Conditions
C3 Glomerulopathy (C3G)
Interventions
DRUG

Avacopan

Orally administered

DRUG

Avacopan Matching Placebo

avacopan matching placebo

Trial Locations (45)

6500

Clinical Site, Nijmegen

6525

Clinical Site, Nijmegen

10032

Clinical Site, New York

14625

Clinical Site, Rochester

19107

Clinical Site, Philadelphia

43210

Clinical Site, Columbus

52242

Clinical Site, Iowa City

60611

Clinical Site, Chicago

84132

University of Utah, Salt Lake City

94305

Clinical Site, Palo Alto

02114

Clinical Site, Boston

02914

Clinical Trial Site, East Providence

Unknown

Clinical Site, Antwerp

Clinical Site, Brussels

Clinical Site, Leuven

Clinical Site, Liège

Clinical Site, Vancouver

Clinical Site, Calgary

Clinical Site, Aalborg

Clinical Site, Copenhagen

Clinical Site, Odense

Clinical Site, Boulogne-sur-Mer

Clinical Site, Grenoble

Clinical Site, Paris

Clinical Site, Valenciennes

Clinical Site, Dresden

Clinical Site, Essen

Clinical Site, Hanover

Clinical Site, Lübeck

Clinical Site, Munich

Clinical Site, Dublin

Clinical Site, Bergamo

Clinical Site, Bologna

Clinical Site, Milan

Clinical Site, Parma

Clinical Site, Roma

Clinical Site, Amsterdam

Clinical Site, Leiden

Clinical Site, Burela de Cabo

Clinical Site, Madrid

Clinical Site, London

Clinical Site, Newcastle upon Tyne

9713 GZ

Groningen UMC, Groningen

08025

Clinical Site, Barcelona

08035

Clinical Site, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Amgen

INDUSTRY